本页面由Tiger Trade Technology Pte. Ltd.提供服务

Ultragenyx Pharmaceutical Inc

15.30
-0.1800-1.16%
盘前:15.20-0.1000-0.65%07:32 EDT
成交量:289.86万
成交额:4,426.93万
市值:15.04亿
市盈率:-2.63
高:15.49
开:15.42
低:15.10
收:15.48
52周最高:39.89
52周最低:12.73
股本:9,831.72万
流通股本:8,071.56万
量比:0.69
换手率:3.59%
股息:- -
股息率:- -
每股收益(TTM):-5.8279
每股收益(LYR):-5.8316
净资产收益率:-608.47%
总资产收益率:-24.22%
市净率:-5.17
市盈率(LYR):-2.62

数据加载中...

2026/10/07

重要事件披露

Form 8-K - Current report
2026/09/17

重要事件披露

Form 8-K - Current report
2026/09/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/09/03

重要事件披露

Form 8-K - Current report
2026/08/19

重要事件披露

Form 8-K - Current report
2026/08/14

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/08/13

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/08/11

重要事件披露

Form 8-K - Current report
2026/08/07

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/08/05

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/08/05

重要事件披露

Form 8-K - Current report
2026/08/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/07/31

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/07/31

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/07/30

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/07/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/06/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/06/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/06/12

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2026/06/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities